Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

finance.yahoo.com/news/rallybio-sell-interest-rev102-recursion-121604431.html

In This Article:
Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia, to joint venture partner Recursion Pharmaceuticals (RXRX) for up…

This story appeared on finance.yahoo.com, 2025-07-09 12:16:04.
The Entire Business World on a Single Page. Free to Use →